CNS & neuromuscular denials at external review

• among the highest

  At 70.7%, this is the 3rd highest overturn rate of the 24 conditiones with enough decisions to publish one. Reviewers sustained the plan in the remaining 29.3% of disputes.

• rising

  It has risen over the published record: 21.3% in 2002 against 75.7% in 2025. What drove that is not in this data — the file holds outcomes, not who chose to appeal or how plans changed their own review.

• most-cited standard

  Reviewers named FDA more than any other standard here — 264 decisions, which came out at 82.2%, 12 points above the class as a whole. Citing a standard and the outcome share a cause; this is not the effect of naming it.

• concentrated

  50% of these disputes involved pharmacy alone (n=463, 76.7% overturned), so the headline figure for cns & neuromuscular is largely that pairing.

California requires each published decision to carry “a detailed case summary that includes the specific standards, criteria, and medical and scientific evidence, if any, that led to the case decision” (Health & Safety Code § 1374.33(h)(1)(K)). These are the elements our extraction found in this class, split by how the decision came out.

Read as description, not instruction. These are patterns in what reviewers wrote, not steps to follow, and no combination of them predicts an outcome. Only codes that cleared the validation gate appear — thirteen did not.

• FDA82.2%264
• American Headache Society78.4%74
• American Academy of Neurology83.7%43
• American College of Rheumatology—12
• NCCN—4
• LOCUS family—3
• American Academy of Child and Adolescent Psychiatry—1
• American Academy of Ophthalmology—1

A rate here is the outcome of decisions that named the authority, not the effect of naming it. Reviewers cite the standard they applied; the citation and the outcome share a cause.

• Pharmacy76.7%463
• Durable medical equipment51.4%111
• Pain Management75.0%88
• Diagnostic imaging & screening64.1%78
• Ear, nose & throat procedures83.9%31
• Electro, thermal & radiofrequency70.0%30
• Neurosurgery90.0%30
• Skilled nursing & inpatient rehab—15

Browse all treatment classes · Pick your own pair

• Other67.8%202
• Migraine Rx82.5%126
• Neuromuscular RX90.1%71
• Nerve Block80.0%60
• IVIG Therapy62.0%50
• Botox Injection83.0%47
• Pain Medication53.3%30
• Biologics—29

• Medical Necessity69.4%689
• Experimental/Investigational74.4%234
• Urgent Care—2

Medical-necessity review asks whether the care is needed. Experimental/investigational review asks whether it is likely to be more beneficial than standard therapy — a harder statutory test, and the rates show it.